03.06.2013 - GlaxoSmithKline’s multi kinase blocker pazopanib has increased progression free survival in women with advanced ovarian cancer by 5.6 months.
At the ASCO meeting, the British drug major reported that the median time to disease progression under the VEGFR, PDGFR, c-KIT blocker post-surgery and chemotherapy was 17.9 months, compared with 12.3 months in patients receiving placebo. GSK announced that it will file an MAA in the US for pazopanib as first-in-class maintenance therapy after surgery and chemotherapy. In contrast to Europe where Roche’s bevacizumab is approved as maintenance therapy, there is no comparable treatment approved by the FDA.
91% of the 940 patients with advanced epithelial ovarian cancer had stage III/IV disease at diagnosis and no residual disease following surgery. While efficacy was shown, more serious adverse drug effects were observed in the pazopanib group (26%) than in the placebo arm (11%) of the study.
07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.
03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.